As a result, we tested drug-sensitivity after CD38 handling: as expected, the higher activity of FK866 was found in CD38-overexpressing MM cells than the control (Figure 1E and Figure S2); similarly, another NAD+-lowering agent, GMX-1777, summarized these data (Figure S3). This evidence concerns the gene CD38 and Miyoshi myopathy.